Time filter

Source Type

Mahmood Baig S.,National Institute for Biotechnology and Genetic Engineering NIBGE | Sabih D.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Rahim M.K.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Azhar A.,National Institute for Biotechnology and Genetic Engineering NIBGE | And 12 more authors.
Journal of Pediatric Hematology/Oncology | Year: 2012

Prenatal diagnosis (PND) of β-thalassemia has been underutilized in Pakistan because of a number of social and economic factors. National Institute for Biotechnology and Genetic Engineering Faisalabad in collaboration with Multan Institute of Nuclear Medicine and Radiotherapy Multan introduced free PND service for carrier couples of Multan district. Multan has a population of about 4 million. More than 170 couples registered for retrospective PND and in 2 years 105 PND were carried out through first trimester chorionic villus sampling. Almost 90% of these couples were unable to afford the cost of PND and would not have undergone the test as free service was not available. Monoplex and Multiplex Amplification Refractory Mutation System-polymerase chain reaction and genomic DNA sequencing were used for detection of IVS (intervening sequence)-I-5 (G-C), FSC (frameshift codon)-8/9 (+G), FSC-41/42 (-TTCT), IVS-I-1 (G-T), 619 bp deletion, and CD-15 (G-A) β-globin mutations. Eighty-one percent (85/105) couples analyzed were in a consanguineous marriage. Twenty-three fetuses were found homozygous mutant and all couples opted for discontinuation of affected pregnancies. More families are registering for PND after establishment of this free and accessible PND service. Copyright © 2011 by Lippincott Williams & Wilkins.


Minhas F.U.A.A.,Colorado State University | Sabih D.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Hussain M.,Pakistan Institute of Engineering and Applied Sciences
Journal of Medical Systems | Year: 2012

This paper presents a novel approach for detection of Fatty liver disease (FLD) and Heterogeneous liver using textural analysis of liver ultrasound images. The proposed system is able to automatically assign a representative region of interest (ROI) in a liver ultrasound which is subsequently used for diagnosis. This ROI is analyzed using Wavelet Packet Transform (WPT) and a number of statistical features are obtained. A multi-class linear support vector machine (SVM) is then used for classification. The proposed system gives an overall accuracy of ~95% which clearly illustrates the efficacy of the system. © 2011 Springer Science+Business Media, LLC.


Mahmood R.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Parveen S.,Nishtar Medical College | Kanwal S.,Allama Iqbal Medical College
Pakistan Journal of Medical and Health Sciences | Year: 2015

Background: Infection by HBV and HCV is the most serious health problem in our country especially in the southern Punjab. Very few studies exist on incidence of this infection but they hardly reflect our general population. Aim: To find the prevalence of hepatic infection in the general population of southern Punjab. Methods: A total of 120 euthyroid patients (males: 36 Females: 84) who visited MINAR for thyroid tests during December 2010-11 were included in this study. The mean age of these persons was 30.7±.09 years (range 18-52 years). The patients with thyroid disorders and other infectious or non-infectious disease were excluded. Serum was tested for HBC and HCV detection using commercially supplied kits of HBS (One Step Test Device) and HCV (One Step Test Device) for qualitative detection of HBS or HCV. The principle of the test was rapid chromatographic immunoassay for the qualitative detection HBS and ani-HCV. T3, T4 and TSH were measured by RIA methods. Results: Out of 120 subjects 4(3.3%) were found positive for HBsAg and 18(15%) were found positive for anti-HCV. Statistical comparison of this data showed that prevalence of HCV infection was about 4 times higher than HBV infection (p=0.00028). Prevalence of HBsAg in males (8%) was significantly higher than females (1.2%; p<0.006345) whereas prevalence of HCV in males (16.7%) was not significantly different from females ((14.2%;p=0.521303). Comparison of groups of males positive for HCV and HBS showed that the incidence of HCV infection (16.7%) was significantly higher than HBS (8.33%). (p=0.0102). Similarly comparison of groups of females positive for HCV and HBS showed that the incidence of HCV infection (14.2%) was significantly higher p=0.000011) than HBS (1.2%). Conclusion: The increased level of HCV infection in our population is alarming and needs extensive studies and preventive measures in future.


Mateen A.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Javed A.A.,Nishtar Hospital | Masood A.I.,Nishtar Hospital
Chinese-German Journal of Clinical Oncology | Year: 2012

Objective: Hepatocellular carcinoma (HCC) is among the most common and rapidly increasing cancers in Pakistan. There is currently no standard management for advanced HCC. The aim of the study was to assess response rate and toxicity of concomitant gemcitabine and external radiation therapy (ERT) in locally advanced HCC. Methods: Sixty patients were enrolled. Gemcitabine, 70 mg/m 2 was given weekly during ERT. ERT was delivered with 60Co beam up to 30.6 Gy, 1.8 Gy/fraction. Tumor response was assessed by computed tomography (CT) at eight weeks. Complete and partial response (CR and PR), progressive and stable disease (PD and SD) were assessed. Hematological, gastrointestinal and hepatic toxicities were assessed weekly. Results: No CR was seen. PR, SD and PD were seen in 33%, 40% and 27% of patients respectively. Grade 3/4 toxicity for total leukocyte count and platelets was observed in 7% and 27% patients. Grade 3/4 toxicity for liver failure, bilirubin, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase was seen in 35%, 28%, 38%, 24% and 43% patients respectively. Conclusion: The study showed that concomitant gemcitabine and ERT is a feasible option with moderate toxicity in advanced HCC. © Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2012.


Khan S.A.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Khan M.S.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Arif M.,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | Durr-e-Sabih,Multan Institute of Nuclear Medicine and Radiotherapy MINAR | And 2 more authors.
Journal of the College of Physicians and Surgeons Pakistan | Year: 2015

Objective: To determine the patterns of dose rate reduction in single and multiple radioiodine (I-131) therapies in cases of well differentiated thyroid cancer patients. Study Design: Analytical series. Place and Duration of Study: Department of Nuclear Medicine and Radiation Physics, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR), Multan, Pakistan, from December 2006 to December 2013. Methodology: Ninety three patients (167 therapies) with well differentiated thyroid cancer treated with different doses of I-131 as an in-patient were inducted. Fifty four patients were given only single I-131 therapy dose ranging from 70 mCi (2590 MBq) to 150 mCi (5550 MBq). Thirty nine patients were treated with multiple I-131 radioisotope therapy doses ranging from 80 mCi (2960 MBq) to 250 mCi (9250 MBq). T-test was applied on the sample data showed statistically significant difference between the two groups with p-value (p < 0.01) less than 0.05 taken as significant. Results: There were 68 females and 25 males with an age range of 15 to 80 years. Mean age of the patients were 36 years. Among the 93 cases of first time Radio Active Iodine (RAI) therapy, 59 cases (63%) were discharged after 48 hours. Among 39 patients who received RAI therapy second time or more, most were discharged earlier after achieving acceptable discharge dose rate i.e 25 μSv/hour; 2 out of 39 (5%) were discharged after 48 hours. In 58% patients, given single I-131 therapy dose, majority of these were discharged after 48 hours without any major complications. Conclusion: For well differentiated thyroid cancer patients, rapid dose rate reduction is seen in patients receiving second or subsequent radioiodine (RAI) therapy, as compared to first time receiving RAI therapy.


PubMed | Multan Institute of Nuclear Medicine and Radiotherapy MINAR
Type: Comparative Study | Journal: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP | Year: 2015

To determine the patterns of dose rate reduction in single and multiple radioiodine (I-131) therapies in cases of well differentiated thyroid cancer patients.Analytical series.Department of Nuclear Medicine and Radiation Physics, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR), Multan, Pakistan, from December 2006 to December 2013.Ninety three patients (167 therapies) with well differentiated thyroid cancer treated with different doses of I-131 as an in-patient were inducted. Fifty four patients were given only single I-131 therapy dose ranging from 70 mCi (2590 MBq) to 150 mCi (5550 MBq). Thirty nine patients were treated with multiple I-131 radioisotope therapy doses ranging from 80 mCi (2960 MBq) to 250 mCi (9250 MBq). T-test was applied on the sample data showed statistically significant difference between the two groups with p-value (p < 0.01) less than 0.05 taken as significant.There were 68 females and 25 males with an age range of 15 to 80 years. Mean age of the patients were 36 years. Among the 93 cases of first time Radio Active Iodine (RAI) therapy, 59 cases (63%) were discharged after 48 hours. Among 39 patients who received RAI therapy second time or more, most were discharged earlier after achieving acceptable discharge dose rate i.e 25 Sv/hour; 2 out of 39 (5%) were discharged after 48 hours. In 58% patients, given single I-131 therapy dose, majority of these were discharged after 48 hours without any major complications.For well differentiated thyroid cancer patients, rapid dose rate reduction is seen in patients receiving second or subsequent radioiodine (RAI) therapy, as compared to first time receiving RAI therapy.

Loading Multan Institute of Nuclear Medicine and Radiotherapy MINAR collaborators
Loading Multan Institute of Nuclear Medicine and Radiotherapy MINAR collaborators